Analyst Conference Summaries

Biotechnology Investor Aids

Dicerna Pharmaceuticals
DRNA

conference date: November 5, 2020 @ 1:30 PM Pacific Time

Dicerna Pharmaceuticals May Be the Best Value Among RNAi Companies [September 15, 2020 at Seeking Alpha]

Dicerna: An RNA Therapy-Based 21st Century Likely Winner [July 12, 2019 at Seeking Alpha]

2020
Dicerna (DRNA)
Q1 2020
Dicerna (DRNA)
Q2 2020
Dicerna (DRNA)
Q3 2020
 
May 7, 2020 Aug. 6, 2020 Nov. 5, 2020  
2019
  Dicerna (DRNA)
Q2 2019
Dicerna (DRNA)
Q3 2019
Dicerna (DRNA)
Q4 2019
  Aug. 8, 2019 Nov. 7, 2019 Feb. 27, 2020

Dicerna Pharmaceuticals (DRNA) is a clinical-stage biotechnology company specializing in RNA therapies for genetic diseases.

Dicerna Pharmaceuticals web site

I bought my first DRNA on September 14, 2020

 

Search

More Analyst Conference Pages:

 AGEN
 AGIO
 ALNY
 ALXN
 AMAT
 AMGN
 APRE
 ARWR
 BIIB
 BMY
 CLDX
 CLSN
 EPZM
 GILD
 GLYC
 INO
 IONS
 ISRG
 MCHP
 MRNA
 PLX
 RETA
 REGN
 SGEN
 SYRS
 TTPH
 VBLT
 VSTM
 XLNX
 XLRN
       

Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.

Copyright 2020 William P. Meyers